Adrenoleukodystrophy (patient information): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
'''For the WikiDoc page for this topic, click [[Adrenoleukodystrophy|here]]'''
'''For the WikiDoc page for this topic, click [[Adrenoleukodystrophy|here]]'''
 
{{Infobox_Disease |
  Name          = {{PAGENAME}} |
  Image          = |
  Caption        = |
  DiseasesDB    = 292 |
  ICD10          = {{ICD10|E|71|3|e|70}} |
  ICD9          = {{ICD9|330.0}}, {{ICD9|277.86}} |
  ICDO          = |
  OMIM          = 300100 |
  OMIM_mult      = {{OMIM2|202370}} |
  MedlinePlus    = |
  eMedicineSubj  = |
  eMedicineTopic = |
  MeshID        = D000326 |
}}
{{SI}}
{{SI}}


'''Editor-in-Chief:''' Alexandra M. Palmer
{{CMG}}; '''Assistant Editor(s)-In-Chief:''' Alexandra M. Palmer
 
{{EJ}}


==What is Adrenoleukodystrophy?==
==Overview==
[[Adrenoleukodystrophy]] describes several closely related [[inherited]] [[disorders]] that disrupt the breakdown ([[metabolism]]) of certain [[fats]] (very-long-chain [[fatty acids]]).
[[Adrenoleukodystrophy]] describes several closely related [[inherited]] [[disorders]] that disrupt the breakdown ([[metabolism]]) of certain [[fats]] (very-long-chain [[fatty acids]]).


Line 49: Line 61:
*Impaired [[adrenal gland]] function (called [[Addison disease]] or Addison-like [[phenotype]]) -- [[adrenal gland]] does not produce enough [[steroid hormones]]
*Impaired [[adrenal gland]] function (called [[Addison disease]] or Addison-like [[phenotype]]) -- [[adrenal gland]] does not produce enough [[steroid hormones]]


==Who is at risk for Adrenoleukodystrophy?==
==Who is at highest risk?==
[[Adrenoleukodystrophy]] is a [[genetic disorder]], so anyone with a [[family history]] of the [[disorder]] is at risk. Since the [[disease]] is passed down from parents to their children as an [[X-linked]] [[genetic trait]], [[males]] are mostly affected.
[[Adrenoleukodystrophy]] is a [[genetic disorder]], so anyone with a [[family history]] of the [[disorder]] is at risk. Since the [[disease]] is passed down from parents to their children as an [[X-linked]] [[genetic trait]], [[males]] are mostly affected.


==How do I know I have Adrenoleukodystrophy?==
==How to know you have Adrenoleukodystrophy?==
*[[Blood]] levels
*[[Blood]] levels
*[[Chromosome]] study to look for changes ([[mutations]]) in the [[ABCD1]] gene
*[[Chromosome]] study to look for changes ([[mutations]]) in the [[ABCD1]] gene
*[[MRI]] of the [[head]]
*[[MRI]] of the [[head]]


==When to seek urgent medical care==
==When to seek urgent medical care?==
Call your [[health care provider]] if:
Call your [[health care provider]] if:
*Your child develops symptoms of [[X-linked]] [[adrenoleukodystrophy]]
*Your child develops symptoms of [[X-linked]] [[adrenoleukodystrophy]]
Line 71: Line 83:
[[Bone marrow transplant]] is also being tested as an experimental treatment.
[[Bone marrow transplant]] is also being tested as an experimental treatment.


==Where to find medical care for Adrenoleukodystrophy==
==Where to find medical care for Adrenoleukodystrophy?==
[http://maps.google.com/maps?f=q&hl=en&geocode=&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|Adrenoleukodystrophy}}}}&sll=37.0625,-95.677068&sspn=65.008093,112.148438&ie=UTF8&ll=37.0625,-95.677068&spn=91.690419,149.414063&z=2&source=embed    Directions to Hospitals Treating Adrenoleukodystrophy]
[http://maps.google.com/maps?f=q&hl=en&geocode=&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|Adrenoleukodystrophy}}}}&sll=37.0625,-95.677068&sspn=65.008093,112.148438&ie=UTF8&ll=37.0625,-95.677068&spn=91.690419,149.414063&z=2&source=embed    Directions to Hospitals Treating Adrenoleukodystrophy]


==What to expect (Outlook/Prognosis)==
==What to expect (Outlook/Prognosis)?==
The [[childhood]] form of [[X-linked]] [[adrenoleukodystrophy]] is a progressive [[disease]] that leads to a long-term [[coma]] ([[vegetative state]]) about 2 years after [[neurological]] symptoms develop. The child can live in this [[condition]] for as long as 10 years until [[death]] occurs.
The [[childhood]] form of [[X-linked]] [[adrenoleukodystrophy]] is a progressive [[disease]] that leads to a long-term [[coma]] ([[vegetative state]]) about 2 years after [[neurological]] symptoms develop. The child can live in this [[condition]] for as long as 10 years until [[death]] occurs.


Line 87: Line 99:


[[Category:Patient information]]
[[Category:Patient information]]
[[Category:Genetic disorders patient information]]
[[Category:Inborn errors of metabolism patient information]]
[[Category:Inborn errors of metabolism patient information]]
[[Category:Inborn errors of metabolism]]
[[Category:Inborn errors of metabolism]]
[[Category:Disease state]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]



Revision as of 19:07, 29 July 2011

For the WikiDoc page for this topic, click here

Adrenoleukodystrophy (patient information)
ICD-10 E71.3
ICD-9 330.0, 277.86
OMIM 300100 202370
DiseasesDB 292
MeSH D000326

WikiDoc Resources for Adrenoleukodystrophy (patient information)

Articles

Most recent articles on Adrenoleukodystrophy (patient information)

Most cited articles on Adrenoleukodystrophy (patient information)

Review articles on Adrenoleukodystrophy (patient information)

Articles on Adrenoleukodystrophy (patient information) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Adrenoleukodystrophy (patient information)

Images of Adrenoleukodystrophy (patient information)

Photos of Adrenoleukodystrophy (patient information)

Podcasts & MP3s on Adrenoleukodystrophy (patient information)

Videos on Adrenoleukodystrophy (patient information)

Evidence Based Medicine

Cochrane Collaboration on Adrenoleukodystrophy (patient information)

Bandolier on Adrenoleukodystrophy (patient information)

TRIP on Adrenoleukodystrophy (patient information)

Clinical Trials

Ongoing Trials on Adrenoleukodystrophy (patient information) at Clinical Trials.gov

Trial results on Adrenoleukodystrophy (patient information)

Clinical Trials on Adrenoleukodystrophy (patient information) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Adrenoleukodystrophy (patient information)

NICE Guidance on Adrenoleukodystrophy (patient information)

NHS PRODIGY Guidance

FDA on Adrenoleukodystrophy (patient information)

CDC on Adrenoleukodystrophy (patient information)

Books

Books on Adrenoleukodystrophy (patient information)

News

Adrenoleukodystrophy (patient information) in the news

Be alerted to news on Adrenoleukodystrophy (patient information)

News trends on Adrenoleukodystrophy (patient information)

Commentary

Blogs on Adrenoleukodystrophy (patient information)

Definitions

Definitions of Adrenoleukodystrophy (patient information)

Patient Resources / Community

Patient resources on Adrenoleukodystrophy (patient information)

Discussion groups on Adrenoleukodystrophy (patient information)

Patient Handouts on Adrenoleukodystrophy (patient information)

Directions to Hospitals Treating Adrenoleukodystrophy (patient information)

Risk calculators and risk factors for Adrenoleukodystrophy (patient information)

Healthcare Provider Resources

Symptoms of Adrenoleukodystrophy (patient information)

Causes & Risk Factors for Adrenoleukodystrophy (patient information)

Diagnostic studies for Adrenoleukodystrophy (patient information)

Treatment of Adrenoleukodystrophy (patient information)

Continuing Medical Education (CME)

CME Programs on Adrenoleukodystrophy (patient information)

International

Adrenoleukodystrophy (patient information) en Espanol

Adrenoleukodystrophy (patient information) en Francais

Business

Adrenoleukodystrophy (patient information) in the Marketplace

Patents on Adrenoleukodystrophy (patient information)

Experimental / Informatics

List of terms related to Adrenoleukodystrophy (patient information)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor(s)-In-Chief: Alexandra M. Palmer

Overview

Adrenoleukodystrophy describes several closely related inherited disorders that disrupt the breakdown (metabolism) of certain fats (very-long-chain fatty acids).

What are the symptoms of Adrenoleukodystrophy?

Childhood cerebral type:

Adrenomyelopathy:

Adrenal gland failure (Addison type):

What causes Adrenoleukodystrophy?

Adrenoleukodystrophy is passed down from parents to their children as an X-linked genetic trait. It therefore affects mostly males, although some women who are carriers can have milder forms of the disease. It affects approximately 1 in 20,000 people from all races.

The condition results in the buildup of very-long-chain fatty acids in the nervous system, adrenal gland, and testes, which disrupts normal activity. There are three major categories of disease:

Who is at highest risk?

Adrenoleukodystrophy is a genetic disorder, so anyone with a family history of the disorder is at risk. Since the disease is passed down from parents to their children as an X-linked genetic trait, males are mostly affected.

How to know you have Adrenoleukodystrophy?

When to seek urgent medical care?

Call your health care provider if:

Treatment options

Adrenal dysfunction is treated with steroids (such as cortisol).

A specific treatment for X-linked adrenoleukodystrophy is not available, but eating a diet low in very-long-chain fatty acids and taking special oils can lower the blood levels of very-long-chain fatty acids.

These oils are called Lorenzo's oil, after the son of the family who discovered the treatment. This treatment is being tested for X-linked adrenoleukodystrophy, but it does not cure the disease and may not help all patients.

Bone marrow transplant is also being tested as an experimental treatment.

Where to find medical care for Adrenoleukodystrophy?

Directions to Hospitals Treating Adrenoleukodystrophy

What to expect (Outlook/Prognosis)?

The childhood form of X-linked adrenoleukodystrophy is a progressive disease that leads to a long-term coma (vegetative state) about 2 years after neurological symptoms develop. The child can live in this condition for as long as 10 years until death occurs.

The other forms of this disease are milder.

Possible complications

Sources

http://www.nlm.nih.gov/medlineplus/ency/article/001182.htm

Template:SIB Template:WH Template:WS